

Press Release



ASKA Pharmaceutical Holdings Installs CO₂-Free Electricity and Solar Power Generation Facilities

TOKYO, April 21, 2023 - ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo / President, Representative Director: Takashi Yamaguchi, hereinafter “ASKA”) announced that ASKA decided to install CO₂-free electricity and solar power generation facilities.

In April 2023, the Iwaki Factory, a production base of the core subsidiary, ASKA Pharmaceutical (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi), has introduced CO₂-free electricity for some of its electricity use. This will reduce CO₂ emissions by approximately 530 tons per year. ASKA gradually switches to CO₂-free electricity, which will reduce CO₂ emissions by a total of approximately 2,200 tons. Furthermore, ASKA will begin construction and prepare for the solar power generation facilities in order to start supplying electricity in the spring of 2024.

ASKA is committed to becoming carbon neutral by 2050. Furthermore, ASKA has set a goal of reducing CO₂ emissions by 46% (compared to FY2013) by FY2030 in order to contribute to the realization of a decarbonized society. ASKA will continue to explore and implement initiatives to reduce CO₂ emissions.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp